Answers are grounded in this paper and cite their sources.
With the emergence of chemical biology, the use of pharmacological inhibitors in biological research has been expanding. SP600125 is a low-molecular weight compound that has been widely used to inhibit c-Jun-N-terminal kinase (JNK). A recent publication by Tanemura et al. (J. Biochem. 145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110δ), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110α and p110γ. Here, I discuss what we learn from such unpredicted off-target effects of pharmacological inhibitors.
No takes yet. Share an insight, caveat, or question.
Keisuke Miyazawa (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: